Latest news with #ENDO2025
NDTV
5 hours ago
- Health
- NDTV
High Blood Sugar Can Affect Your Sex Life, Research Reveals
A recent research presented at the ENDO 2025 revealed that high blood sugar levels can impact men's sexual health. The research, which has not yet been peer-reviewed, found that even slight elevations in blood sugar levels, below the diabetic threshold, can lead to a decline in sperm movement and erectile function. The researchers analysed the health records of 110 adult men with obesity or type 2 diabetes being treated with weight-loss medications and who were not on testosterone or hormonal therapy. Along with 10% weight loss, the proportion of men with normal levels of both total and free testosterone rose from 53% to 77%. As per the preliminary research presented this week at the Endocrine Society's annual meeting in San Francisco, high blood sugar can lower testosterone levels, which are crucial for male sexual function. Testosterone levels don't directly impact erectile function but rather correlate with libido assessment. The research found that high glucose levels can damage nerves and blood vessels, which are essential for achieving and maintaining erections, leading to erectile dysfunction. Lifestyle Changes And Prevention A balanced diet rich in whole foods and fibre can help stabilise blood sugar and reduce inflammation. Regular physical activity helps in improving insulin sensitivity, and it supports weight loss. Meditation and yoga can enhance mental and emotional well-being, playing a role in sexual performance. Medications like semaglutide, liraglutide and tirzepatide can help regulate blood sugar. "While it is well known that weight loss from lifestyle changes or bariatric surgery increases testosterone levels, the impact that anti-obesity medications may also have on these levels has not been widely studied," said Shellsea Portillo Canales, M.D., endocrinology fellow at SSM Health St. Louis University Hospital in St. Louis, Mo. "Our study is among the first to provide compelling evidence that low testosterone can be reversed with the use of commonly prescribed anti-obesity medications."
Yahoo
6 hours ago
- Business
- Yahoo
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and Phase 2b clinical trials of avexitide for post-bariatric hypoglycemia/PBH at the Endocrine Society's annual meeting (ENDO 2025). Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist and has received FDA Breakthrough Therapy designation for PBH. PBH is a complication that can arise after bariatric surgery, such as Roux-en-Y gastric bypass. A medical scientist in a lab coat gazing at a microscopic view of a drug in development. There are currently no FDA-approved treatments for PBH. Avexitide works by binding to the GLP-1 receptor on pancreatic islet beta cells, blocking the effect of excessive GLP-1 and thus mitigating hypoglycemia by decreasing insulin secretion and stabilizing glucose levels. Avexitide has generally been well-tolerated with a favorable safety profile across all trials. Amylyx expects to complete recruitment for the LUCIDITY trial this year, with topline data anticipated in H1 2026. Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is a clinical-stage pharmaceutical company that discovers and develops treatment options for neurodegenerative diseases and endocrine conditions in the US. While we acknowledge the potential of AMLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Business
- Yahoo
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and Phase 2b clinical trials of avexitide for post-bariatric hypoglycemia/PBH at the Endocrine Society's annual meeting (ENDO 2025). Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist and has received FDA Breakthrough Therapy designation for PBH. PBH is a complication that can arise after bariatric surgery, such as Roux-en-Y gastric bypass. A medical scientist in a lab coat gazing at a microscopic view of a drug in development. There are currently no FDA-approved treatments for PBH. Avexitide works by binding to the GLP-1 receptor on pancreatic islet beta cells, blocking the effect of excessive GLP-1 and thus mitigating hypoglycemia by decreasing insulin secretion and stabilizing glucose levels. Avexitide has generally been well-tolerated with a favorable safety profile across all trials. Amylyx expects to complete recruitment for the LUCIDITY trial this year, with topline data anticipated in H1 2026. Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is a clinical-stage pharmaceutical company that discovers and develops treatment options for neurodegenerative diseases and endocrine conditions in the US. While we acknowledge the potential of AMLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
11 hours ago
- Health
- Medscape
Obesity-Related Cancer Deaths More Than Triple
Cancer deaths related to obesity have risen sharply over the past two decades, especially among older adults, women, non-Hispanic Black individuals and people living with obesity in rural areas, a US study found. 'Obesity is a well-known risk factor for various cancers, but its contribution to cancer-specific mortality over time hasn't been systematically quantified at a national level,' lead investigator Faizan Ahmed, MD, with Jersey Shore University Medical Center, Neptune City, New Jersey, told Medscape Medical News. 'Clinicians should recognize obesity not just as a cardiovascular or metabolic risk factor but as a significant oncologic concern,' Ahmed said. He presented his research on July 13 at ENDO 2025, The Endocrine Society Annual Meeting in San Francisco. Higher Risk for 13 Cancers According to the CDC, 40% of adults are living with obesity. Obesity is associated with a higher risk for 13 cancers, which make up 40% of all cancers diagnosed in the US each year. They are adenocarcinoma of the esophagus, postmenopausal breast cancer, as well as cancer of the colon and rectum, uterus, gallbladder, upper stomach, kidneys, liver, ovaries, pancreas, thyroid, meningioma, and multiple myeloma. To see the trends in obesity-associated cancer deaths over the past two decades, Ahmed and colleagues analyzed CDC data for 33,572 obesity and cancer-related deaths. They found that the overall age-adjusted mortality rate gradually increased from 3.73 per million in 1999 to 13.52 per million in 2020. 'That's more than a tripling in obesity-related cancer mortality rates over 20 years — a striking rise,' Ahmed told Medscape Medical News . 'To put it in context, this is a steeper increase than seen in many other chronic disease mortality trends during the same time period. It signals a rapidly escalating public health burden,' he noted. Overall, the average percent change from 2018-2020 was +19.4%. The average annual percentage change was also statistically significant at 5.92 ( P < .000001). In stratified analyses, the overall age-adjusted mortality rate per million was greater in women than in men (7.22 vs 6.59), in non-Hispanic Black persons than in non-Hispanic White persons (9.20 vs 7.13), and in adults aged 65+ than those aged 25-64 (20.82 vs 3.54). Age-adjusted mortality rates from obesity-associated cancers were also higher in rural than in urban areas (9.45 vs 6.40). By region, overall, the Midwest had the highest rates and the Northeast had the lowest rates. State-level analysis revealed that Vermont, Minnesota, and Oklahoma had the highest rates, while Utah, Alabama, and Virginia had the lowest. Underappreciated Link The link between obesity and cancer-related mortality is 'often underappreciated,' Ahmed told Medscape Medical News . 'Our findings emphasize the need to prioritize obesity screening and management as part of comprehensive cancer prevention. Counseling patients on weight management should be reframed as a critical component of reducing long-term cancer risk,' he said. Ahmed also noted that socioeconomic factors could be driving the increase in obesity-related cancer deaths. 'While BMI is a contributing factor, disparities in socioeconomic status, access to preventive care, delays in diagnosis, environmental exposures, and cultural factors likely play a larger role in the observed variations across gender and race.' 'For instance, women may face more delayed diagnoses due to under prioritized symptoms, and certain minority groups may encounter systemic barriers to cancer screening and obesity treatment,' Ahmed said. To tackle the problem of rising rates of obesity-related cancer deaths, Ahmed said policy initiatives should move from downstream management to upstream prevention. This would include 'universal access to cancer screening programs, regardless of income or geography; public health campaigns that normalize obesity management as a cancer prevention strategy; policies promoting equitable access to healthy foods, physical activity, and early intervention services; incentives for primary care to integrate weight management into routine visits; and investment in community-based care models targeting underserved populations,' Ahmed told Medscape Medical News .
Business Insider
21 hours ago
- Business
- Business Insider
Ascendis Pharma announces new data from PaTHway Trial at ENDO 2025
Ascendis Pharma (ASND) announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with TransCon PTH continued to provide a durable response in adults with hypoparathyroidism regardless of its cause, including improvements in biochemistries, kidney function, and quality of life. Results were shared at ENDO 2025, the annual meeting of the Endocrine Society being held in San Francisco. PaTHway was a Phase 3, randomized, double-blind, placebo-controlled 26-week trial of 82 adults with chronic hypoparathyroidism, followed by an open-label extension period through Week 182. During the initial 26-week blinded period, participants were randomized 3:1 TransCon PTH:placebo. Renal function was assessed by estimated glomerular filtration rate. Safety assessments included 24-hour urine-calcium and treatment-emergent adverse events. Hypoparathyroidism-related symptoms, functioning, and well-being were measured by the Hypoparathyroidism Patient Experience Scale. Overall retention in the trial was high, with 73 of the original 82 adults enrolled completing the 3.5-year trial. At Week 156, 64 patients had normal albumin-adjusted serum calcium levels and 70 patients were independent from conventional therapy. Reflecting clinically meaningful improvements in kidney function, improvements in eGFR from baseline were sustained through Week 156: mean eGFR increased by 8.76 mL/min/1.73 m2 across all participants and by 13.98 mL/min/1.73 m2 in participants with baseline eGFR less than 60. Patients in the trial reported continued improvements from baseline in their hypoparathyroidism-related symptoms and health-related quality of life and showed continued normalization of 24-hour urine calcium excretion through Week 156. In the trial, TransCon PTH treatment was generally well-tolerated, with no new safety signals identified. TEAEs were mostly mild or moderate and no serious TEAEs or discontinuations were related to study drug. Elevate Your Investing Strategy:
